Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Managing dyslipidemia in stroke is essential. During the past several decades, monumental changes in dyslipidemia management have occurred, resulting in improvement in outcomes of patients with cardiovascular disease (CVD). The mainstay of the changes has been related to statin therapy, which preven...
Saved in:
Published in | Precision and future medicine Vol. 4; no. 1; pp. 9 - 20 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Sungkyunkwan University School of Medi
01.03.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Managing dyslipidemia in stroke is essential. During the past several decades, monumental changes in dyslipidemia management have occurred, resulting in improvement in outcomes of patients with cardiovascular disease (CVD). The mainstay of the changes has been related to statin therapy, which prevents recurrence of vascular events in patients with established CVD. Very recently proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors have introduced a highly efficient level of lipid lowering practice into cardiovascular field. Vast evidence has established and validated the beneficial effects of statin and PCSK-9 inhibitors in CVD. In addition, there have been extensive changes in guidelines pertaining to dyslipidemia management of CVD patients. However, assessing the direct benefits of these agents, specifically and primarily in patients with stroke, has been less of a focus of clinical studies leaving many unanswered questions open. This review covers the current and available evidence and clinical practice guidelines addressing lipid-lowering therapy in stroke. Furthermore, several specific issues related to lipid-lowering therapies in stroke will be addressed such as statin-related risk of hemorrhagic stroke, statin use in non-atherosclerotic stroke subtype, and non-statin lipid-lowering therapies. |
---|---|
AbstractList | Managing dyslipidemia in stroke is essential. During the past several decades, monumental changes in dyslipidemia management have occurred, resulting in improvement in outcomes of patients with cardiovascular disease (CVD). The mainstay of the changes has been related to statin therapy, which prevents recurrence of vascular events in patients with established CVD. Very recently proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors have introduced a highly efficient level of lipid lowering practice into cardiovascular field. Vast evidence has established and validated the beneficial effects of statin and PCSK-9 inhibitors in CVD. In addition, there have been extensive changes in guidelines pertaining to dyslipidemia management of CVD patients. However, assessing the direct benefits of these agents, specifically and primarily in patients with stroke, has been less of a focus of clinical studies leaving many unanswered questions open. This review covers the current and available evidence and clinical practice guidelines addressing lipid-lowering therapy in stroke. Furthermore, several specific issues related to lipid-lowering therapies in stroke will be addressed such as statin-related risk of hemorrhagic stroke, statin use in non-atherosclerotic stroke subtype, and non-statin lipid-lowering therapies. |
Author | Liebeskind, David S. Bang, Oh Young Seo, Woo-Keun Hosseini, Mersedeh Bahr |
Author_xml | – sequence: 1 givenname: Woo-Keun surname: Seo fullname: Seo, Woo-Keun – sequence: 2 givenname: Mersedeh Bahr surname: Hosseini fullname: Hosseini, Mersedeh Bahr – sequence: 3 givenname: Oh Young surname: Bang fullname: Bang, Oh Young – sequence: 4 givenname: David S. surname: Liebeskind fullname: Liebeskind, David S. |
BookMark | eNo9kNtqAjEQhkOxUGu97u2-wNpsDpukd0V6EIRCsdchm0wk1j2QxIJv31WLczPDz8838N2jSdd3gNBjhReESiqfBt8uCCZ4gcdRN2hKOJalUFxNrjfDd2ie0m5skEpgpaop2nyBhS4Xh8GZDKkIXeGOaR-G4KANpmhNZ7bQjpXnYoCYBrA5_F6KKcf-B8pTFnywRQr5YHLouwd0680-wfx_z9D32-tm-VGuP99Xy5d1aYmQuSQgcM1ogylYJmxlGXOKewzW185VNaiGgwEvuBdCOGVVw4SRNaUNxd7WdIZWF67rzU4PMbQmHnVvgj4HfdxqE3Owe9CSSS4pAd4IYHVFm3p8YgBIIygn2I6spwvLxj6lCP7Kq7A-O9ajY31yrM-O6R8v1HLZ |
CitedBy_id | crossref_primary_10_3390_medicina57060616 crossref_primary_10_1016_j_heliyon_2022_e10218 |
Cites_doi | 10.1016/j.brainresrev.2007.10.010 10.1161/STROKEAHA.110.596734 10.1097/MD.0000000000003186 10.1016/j.jvs.2006.10.008 10.1136/bmj.d1250 10.1056/NEJMoa1105803 10.3390/jcm8071085 10.1016/j.ebiom.2015.08.006 10.1016/S1474-4422(09)70058-4 10.1161/STROKEAHA.107.493106 10.1007/s00415-009-5008-7 10.5853/jos.2015.01578 10.1136/jnnp-2018-318483 10.1177/2396987319838100 10.3389/fneur.2018.00205 10.1161/01.ATV.0000051360.79309.4E 10.5853/jos.2015.17.3.282 10.1001/jama.2016.13985 10.1056/NEJMoa1701329 10.1038/ng1161 10.1056/NEJMoa1510926 10.1212/01.WNL.0000161844.00797.73 10.1093/eurheartj/ehz455 10.1161/01.STR.31.10.2442 10.1111/ijs.12256 10.1161/STROKEAHA.108.534107 10.1038/s41440-018-0165-7 10.5853/jos.2018.01585 10.1111/j.1471-4159.2004.02980.x 10.1161/01.cir.0000437738.63853.7a 10.1177/2047487319830503 10.1016/j.atherosclerosissup.2004.08.026 10.1161/01.STR.0000165920.67784.58 10.1001/jama.2008.621 10.1161/STROKEAHA.114.005518 10.1186/s12883-015-0376-3 10.2337/ds18-0009 10.1161/hc3501.095214 10.1161/JAHA.117.005996 10.1056/NEJMoa1410489 10.1159/000356114 10.1161/STROKEAHA.107.189063 10.1517/14740331003662620 10.1161/01.STR.32.4.980 10.1161/ATVBAHA.107.150748 10.1161/STROKEAHA.117.017623 10.1161/01.STR.0000048213.18751.52 10.1161/01.STR.0000057812.51734.FF 10.1161/CIRCULATIONAHA.106.174516 10.1136/bmj.38855.610324.80 10.1161/01.CIR.0000133317.49796.0E 10.1111/ijs.12624 10.1089/neu.2007.0288 10.1093/eurheartj/ehr158 10.1161/01.ATV.0000044458.23905.3B 10.1056/NEJM198904063201405 10.1056/NEJMoa1910355 10.1056/NEJMoa1801174 10.1212/01.wnl.0000296277.63350.77 10.1002/ana.10555 10.1161/STR.0b013e3181f7d043 10.1016/S0140-6736(04)15690-0 10.1097/MD.0000000000005918 10.5853/jos.2017.01802 10.1161/01.STR.0000199147.30016.74 10.3389/fneur.2019.00052 10.1016/j.jvs.2017.11.029 10.1111/j.1468-1331.2007.02015.x 10.1016/j.ijcard.2014.09.031 10.1056/NEJMoa1615664 10.1016/j.jacc.2018.11.003 10.1161/JAHA.119.013941 10.1056/NEJMoa1612790 10.1093/eurheartj/ehw272 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.23838/pfm.2020.00009 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2508-7959 |
EndPage | 20 |
ExternalDocumentID | oai_doaj_org_article_8485832e5b7e4613b6cf6aee2b73520c 10_23838_pfm_2020_00009 |
GroupedDBID | AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ |
ID | FETCH-LOGICAL-c278t-2e70643b03ec47c1c44d95f0ecf6dd16e9b5eaef75f777d9c9b47a8633b30fc63 |
IEDL.DBID | DOA |
ISSN | 2508-7940 |
IngestDate | Tue Dec 17 15:17:08 EST 2024 Fri Aug 23 01:06:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c278t-2e70643b03ec47c1c44d95f0ecf6dd16e9b5eaef75f777d9c9b47a8633b30fc63 |
OpenAccessLink | https://doaj.org/article/8485832e5b7e4613b6cf6aee2b73520c |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8485832e5b7e4613b6cf6aee2b73520c crossref_primary_10_23838_pfm_2020_00009 |
PublicationCentury | 2000 |
PublicationDate | 2020-03-01 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Precision and future medicine |
PublicationYear | 2020 |
Publisher | Sungkyunkwan University School of Medi |
Publisher_xml | – sequence: 0 name: Sungkyunkwan University School of Medi |
References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref55 ref10 ref54 ref19 ref18 (ref16) 1993; 269 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref40 ref80 ref35 ref79 ref34 ref78 ref37 ref36 ref31 ref75 ref30 ref74 ref33 ref77 ref32 ref76 ref2 (ref5) 2002; 360 ref1 ref39 ref38 (ref11) 1988; 148 ref71 ref70 ref73 ref72 Nodari (ref68) 2007; 3 ref24 ref23 ref67 ref26 ref25 ref69 ref20 ref64 ref63 ref22 ref66 ref21 ref65 (ref17) 2001; 285 ref28 ref27 ref29 Grundy (ref81) 2019; 139 ref60 ref62 ref61 |
References_xml | – ident: ref28 doi: 10.1016/j.brainresrev.2007.10.010 – ident: ref35 doi: 10.1161/STROKEAHA.110.596734 – ident: ref41 doi: 10.1097/MD.0000000000003186 – ident: ref4 doi: 10.1016/j.jvs.2006.10.008 – ident: ref44 doi: 10.1136/bmj.d1250 – ident: ref74 doi: 10.1056/NEJMoa1105803 – ident: ref79 doi: 10.3390/jcm8071085 – ident: ref10 doi: 10.1016/j.ebiom.2015.08.006 – ident: ref65 doi: 10.1016/S1474-4422(09)70058-4 – ident: ref7 doi: 10.1161/STROKEAHA.107.493106 – ident: ref24 – ident: ref57 doi: 10.1007/s00415-009-5008-7 – volume: 139 start-page: e1082 year: 2019 ident: ref81 publication-title: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines contributor: fullname: Grundy – ident: ref40 doi: 10.5853/jos.2015.01578 – ident: ref53 doi: 10.1136/jnnp-2018-318483 – ident: ref66 doi: 10.1177/2396987319838100 – ident: ref61 doi: 10.3389/fneur.2018.00205 – ident: ref25 doi: 10.1161/01.ATV.0000051360.79309.4E – ident: ref42 doi: 10.5853/jos.2015.17.3.282 – ident: ref72 doi: 10.1001/jama.2016.13985 – ident: ref76 doi: 10.1056/NEJMoa1701329 – volume: 360 start-page: 7 year: 2002 ident: ref5 publication-title: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial – ident: ref73 doi: 10.1038/ng1161 – ident: ref77 doi: 10.1056/NEJMoa1510926 – volume: 285 start-page: 2486 year: 2001 ident: ref17 publication-title: Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) – ident: ref58 doi: 10.1212/01.WNL.0000161844.00797.73 – ident: ref23 doi: 10.1093/eurheartj/ehz455 – ident: ref34 doi: 10.1161/01.STR.31.10.2442 – ident: ref39 doi: 10.1111/ijs.12256 – ident: ref56 doi: 10.1161/STROKEAHA.108.534107 – ident: ref55 doi: 10.1038/s41440-018-0165-7 – volume: 3 start-page: 12 year: 2007 ident: ref68 publication-title: The combination of ezetimibe and statin: a new treatment for hypercholesterolemia contributor: fullname: Nodari – ident: ref64 doi: 10.5853/jos.2018.01585 – ident: ref33 doi: 10.1111/j.1471-4159.2004.02980.x – ident: ref13 doi: 10.1161/01.cir.0000437738.63853.7a – ident: ref54 doi: 10.1177/2047487319830503 – ident: ref2 doi: 10.1016/j.atherosclerosissup.2004.08.026 – volume: 148 start-page: 36 year: 1988 ident: ref11 publication-title: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The expert panel – volume: 269 start-page: 3015 year: 1993 ident: ref16 publication-title: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) – ident: ref36 doi: 10.1161/01.STR.0000165920.67784.58 – ident: ref80 doi: 10.1001/jama.2008.621 – ident: ref46 doi: 10.1161/STROKEAHA.114.005518 – ident: ref38 doi: 10.1186/s12883-015-0376-3 – ident: ref14 doi: 10.2337/ds18-0009 – ident: ref1 doi: 10.1161/hc3501.095214 – ident: ref63 doi: 10.1161/JAHA.117.005996 – ident: ref69 doi: 10.1056/NEJMoa1410489 – ident: ref49 doi: 10.1159/000356114 – ident: ref8 doi: 10.1161/STROKEAHA.107.189063 – ident: ref60 doi: 10.1517/14740331003662620 – ident: ref26 doi: 10.1161/01.STR.32.4.980 – ident: ref29 doi: 10.1161/ATVBAHA.107.150748 – ident: ref43 doi: 10.1161/STROKEAHA.117.017623 – ident: ref31 doi: 10.1161/01.STR.0000048213.18751.52 – ident: ref3 doi: 10.1161/01.STR.0000057812.51734.FF – ident: ref19 doi: 10.1161/CIRCULATIONAHA.106.174516 – ident: ref51 doi: 10.1136/bmj.38855.610324.80 – ident: ref18 doi: 10.1161/01.CIR.0000133317.49796.0E – ident: ref52 doi: 10.1111/ijs.12624 – ident: ref32 doi: 10.1089/neu.2007.0288 – ident: ref21 doi: 10.1093/eurheartj/ehr158 – ident: ref27 doi: 10.1161/01.ATV.0000044458.23905.3B – ident: ref50 doi: 10.1056/NEJM198904063201405 – ident: ref67 doi: 10.1056/NEJMoa1910355 – ident: ref70 doi: 10.1056/NEJMoa1801174 – ident: ref9 doi: 10.1212/01.wnl.0000296277.63350.77 – ident: ref30 doi: 10.1002/ana.10555 – ident: ref20 doi: 10.1161/STR.0b013e3181f7d043 – ident: ref6 doi: 10.1016/S0140-6736(04)15690-0 – ident: ref45 doi: 10.1097/MD.0000000000005918 – ident: ref62 doi: 10.5853/jos.2017.01802 – ident: ref12 doi: 10.1161/01.STR.0000199147.30016.74 – ident: ref59 doi: 10.3389/fneur.2019.00052 – ident: ref75 doi: 10.1016/j.jvs.2017.11.029 – ident: ref37 doi: 10.1111/j.1468-1331.2007.02015.x – ident: ref47 doi: 10.1016/j.ijcard.2014.09.031 – ident: ref71 doi: 10.1056/NEJMoa1615664 – ident: ref15 doi: 10.1016/j.jacc.2018.11.003 – ident: ref48 doi: 10.1161/JAHA.119.013941 – ident: ref78 doi: 10.1056/NEJMoa1612790 – ident: ref22 doi: 10.1093/eurheartj/ehw272 |
SSID | ssj0002170991 |
Score | 2.1729515 |
Snippet | Managing dyslipidemia in stroke is essential. During the past several decades, monumental changes in dyslipidemia management have occurred, resulting in... |
SourceID | doaj crossref |
SourceType | Open Website Aggregation Database |
StartPage | 9 |
SubjectTerms | dyslipidemias hydroxymethylglutaryl-coa reductase inhibitors stroke |
Title | Recent updates in dyslipidemia management: perspectives in stroke-specific situation |
URI | https://doaj.org/article/8485832e5b7e4613b6cf6aee2b73520c |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09SwNBEF3EykYUFeMXW1jYHNnb2087FUMQtEog3bGfEMTLkVwK_72zezHGysbmimU5ljfDvjcw-wahWxtLq6TVBaMkwkfwwggDARGhdNHLQLJl_uubGE_Zy4zPdkZ9pZ6w3h64B26omOKQdYFbGRhwjxUuChMCtRK0A3H59iV0p5hKdzAIbZA-qdoCilcFJB3pfX2AoSo1bGN6hE5Jdi_Uvyhpx7k_U8zoCB1utCF-6M90jPZCc4ImIOyAGPC6TbX5Cs8b7D9BHPaTXQ3-2Pav3OP25-Vk3rjqlov3UKS11BGEV_Oud_Y-RdPR8-RpXGxGIRSOStUVNMikHSypgmPSlY4xr3kkAcDwvhRBWx5MiJJHKaXXTlsmjRJVZSsSnajO0H6zaMI5wgYkUam0idom63WqmYncUi-508RLPUB332jUbe94UUOlkIGrAbg6AVdn4AboMaG13ZasqvMCBLDeBLD-K4AX__GTS3SQjtU3h12h_W65DtegFjp7kxPjC95pu_Y |
link.rule.ids | 314,780,784,864,2102,27924,27925 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+updates+in+dyslipidemia+management%3A+perspectives+in+stroke-specific+situation&rft.jtitle=Precision+and+future+medicine&rft.au=Woo-Keun+Seo&rft.au=Mersedeh+Bahr+Hosseini&rft.au=Oh+Young+Bang&rft.au=David+S.+Liebeskind&rft.date=2020-03-01&rft.pub=Sungkyunkwan+University+School+of+Medi&rft.issn=2508-7940&rft.eissn=2508-7959&rft.volume=4&rft.issue=1&rft.spage=9&rft.epage=20&rft_id=info:doi/10.23838%2Fpfm.2020.00009&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8485832e5b7e4613b6cf6aee2b73520c |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2508-7940&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2508-7940&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2508-7940&client=summon |